High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients
about
Low temperature plasma: a novel focal therapy for localized prostate cancer?Low-temperature plasma treatment induces DNA damage leading to necrotic cell death in primary prostate epithelial cellsToxicity outcome in patients treated with modulated arc radiotherapy for localized prostate cancer.Significance of image guidance to clinical outcomes for localized prostate cancerLow incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancerQuality of life of patients after retropubic prostatectomy - pre- and postoperative scores of the EORTC QLQ-C30 and QLQ-PR25.Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot studySingle blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial.Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.Gastrointestinal radiation injury: prevention and treatment.Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking.[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning.The benefit of using bladder sub-volume equivalent uniform dose constraints in prostate intensity-modulated radiotherapy planning.Potential applications of image-guided radiotherapy for radiation dose escalation in patients with early stage high-risk prostate cancer.Choline PET based dose-painting in prostate cancer--modelling of dose effectsTransperineal implantation of gold fiducial markers (gold seeds) for prostate image-guided radiation therapy: a feasible technique associated with a low risk of complications.Challenges and Opportunities in Radiation-induced Hemorrhagic Cystitis.Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy.Reducing radiation-associated toxicity using online image guidance (IGRT) in prostate cancer patients undergoing dose-escalated radiation therapy.Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial.Inter- and intra-observer variability in contouring of the prostate gland on planning computed tomography and cone beam computed tomography.Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy.Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer--predictive factors on irritative symptoms, incontinence and rectal bleeding.Target localization and toxicity in dose-escalated prostate radiotherapy with image-guided approach using daily planar kilovoltage imaging.A study into the relationship between the measured penumbra and effective source size in the modeling of the Pinnacle RTPS.Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer.Image-guided, whole-pelvic, intensity-modulated radiotherapy for biochemical recurrence following radical prostatectomy in high-risk prostate cancer patients.Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life.Immunogenetics of prostate cancer: a still unexplored field of study.Evaluation of gold fiducial marker manual localisation for magnetic resonance-only prostate radiotherapy.Association between rectal bleeding and the absolute dose volume of the rectum following image-guided radiotherapy for patients with prostate cancer.
P2860
Q27027563-6688F1DD-C3A5-414A-B53F-5E9A763FCAA1Q33464674-6D532D92-1A62-460F-8F57-37F89F064C48Q33922165-2E74449A-3E17-46D8-BAA7-CD3DCBEC38DAQ33993238-BAD136CA-B882-4B4B-8EE7-8D3FFAE1FA78Q34871906-AF297D1C-C431-4815-9220-6F31CD65A3EBQ35614582-ADE13CB9-1FAD-4FD2-AE9C-B35E6EF7C9B7Q35684509-BCBF20B8-DE7B-4AE9-AB68-BC3F289F0930Q35777339-82EFB84C-80F3-4806-94D5-8C79ED8F6E5CQ36384072-96EB81BD-30B3-4C85-91FA-31060246C945Q36541213-6F84F2AC-88A5-4809-A0F1-4D15E6F53415Q37035229-9556EA4E-CE88-4125-9E33-A4C1192A8056Q37448735-D20141D2-3809-4AAD-91FF-BA8E9AB12BF8Q37510070-FC296A5D-6181-469F-8605-0B572C34E8E0Q38362692-A01DC9DE-0E30-4CA2-B252-820A79B49472Q38445916-BF9B692C-75EE-491B-86FE-4BEB35BC315BQ38924507-4F48A352-EE06-407E-A680-2CB9DB5529B3Q38948155-E7E59ACE-01BA-452B-9707-101B13E758C6Q39135519-819C63D2-94AC-41AA-BF7E-8DF5CC735D9BQ39415628-65B07B6D-4C57-48C2-B6CF-64C445580B04Q39459690-41E32D77-602D-407B-B3CF-2CA9D3C10333Q39773584-50C85948-BB10-4CCE-816D-79CCAA33B432Q42175056-6A2526E2-5A10-4E95-9F04-744FD6140CEFQ42571229-B194B5A7-623E-4D59-ADA5-63CCC423D345Q46961215-6C695B99-07F1-4181-9071-04903B5F3D90Q47383634-8A3213EC-A939-4003-9A1D-8079860E1730Q47802807-C3CBAF94-EA05-41E5-8B58-1F6294D63D4DQ48269659-93736C8F-2118-45EF-8E2D-621968801595Q48271324-2718C1B0-CCDD-493C-ACD6-BD12E6314A98Q50082109-147F1367-DDC0-448D-83CA-5D862011F6DCQ55428838-31D9A8E2-C916-4DAB-AF02-172530228C9BQ55663443-2BE14572-BDA6-4F1A-8D8E-C3C9DEB6FCDB
P2860
High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
High-dose intensity-modulated ...... late toxicity in 331 patients
@ast
High-dose intensity-modulated ...... late toxicity in 331 patients
@en
type
label
High-dose intensity-modulated ...... late toxicity in 331 patients
@ast
High-dose intensity-modulated ...... late toxicity in 331 patients
@en
prefLabel
High-dose intensity-modulated ...... late toxicity in 331 patients
@ast
High-dose intensity-modulated ...... late toxicity in 331 patients
@en
P2093
P2860
P356
P1433
P1476
High-dose intensity-modulated ...... late toxicity in 331 patients
@en
P2093
Arto E Boeken Kruger
Carla H van Gils
Homan Dehnad
Marco van Vulpen
Uulke A van der Heide
P2860
P2888
P356
10.1186/1748-717X-3-15
P50
P577
2008-05-21T00:00:00Z
P5875
P6179
1040969945